SAN DIEGO, CA, November 22, 2010 – Jaleva Pharmaceuticals LLC announces encouraging pre-clinical results for ‘NicoFix’, Jaleva’s proprietary Nicotine Replacement Therapy product currently under development.
Questcor Pharmaceuticals has signed an agreement with Beacon Pharmaceuticals of Tunbridge Wells, Kent, UK, for the exclusive marketing and distribution of H.P. Acthar(R) Gel in the United Kingdom. More
Norgine and APR, together with its joint venture partner Labtec, today announced that they have entered into an exclusive licensing agreement under which Norgine has acquired the commercialization rights in Europe and selected non-European countries in Mi More
Jaleva Pharmaceuticals LLC is pleased to announce that the FDA has confirmed the regulatory pathway for RelievaDrop, Jaleva’s proprietary transbuccal Nicotine Replacement Therapy (NRT) product currently under development. The FDA confirmed that the pathw More
Innocoll, Inc. announced its sales and marketing subsidiary, Innocoll Pharmaceuticals Ltd., has launched a new version of its CollaRx Gentamicin Surgical Implant that is specially designed for maximum convenience and ease of use in cardiac surgery. More